Results 11 to 20 of about 29,905 (235)
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy [PDF]
Journal of Cardiovascular Development and DiseaseThe management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi +9 more
doaj +2 more sources
Journal of the American College of Cardiology, 2001 This study was designed to compare the hemodynamic efficacy of nonsurgical septal reduction therapy (NSRT) by intracoronary ethanol with standard therapy (surgical myectomy) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).Nonsurgical septal reduction therapy has gained interest as a new treatment modality for patients with drug ...
Sherif Nagueh +2 more
exaly +3 more sources
Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up
Journal of the American College of Cardiology, 2000 The objective of this study is to evaluate the one-year outcome of the first 50 patients who underwent nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy at our institution.Left ventricular outflow tract obstruction is an important determinant of clinical symptoms in patients with hypertrophic obstructive ...
Sherif Nagueh +2 more
exaly +3 more sources
Authors' response: septal reduction therapy for obstructive hypertrophic cardiomyopathy. [PDF]
Eur Heart J OpenSchelldorfer A, Kutz A, Yakupoglu HY.
europepmc +2 more sources
Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes [PDF]
Circulation: Cardiovascular Interventions, 2019 , Carey Kimmelstiel
exaly +2 more sources
ESC Heart Failure, 2023 Aims Mechanical function of the left atrium (LA) and the left ventricle (LV) has been demonstrated to be a prognostic factor in patients with hypertrophic cardiomyopathy (HCM).
Kyung Eun Ha +8 more
doaj +1 more source
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
ESC Heart Failure, 2023 Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority ...
Alexandru Achim +5 more
doaj +1 more source
Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy
Heart International, 2023 Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide.
Milind Y, Desai, Adel, Hajj Ali
openaire +2 more sources
The American Journal of Cardiology, 2022 Ventricular septal myectomy (SM) and alcohol septal ablation (ASA), 2 septal reduction therapies (SRTs), are recommended in symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite maximum tolerated medical therapy. Contradictory results between the outcomes of these 2 types of therapies persist to this day.
Bourque, Catherine +10 more
openaire +5 more sources
Journal of Biomedical & Clinical Research, 2015 Since 1994, alcohol septal ablation (ASA) has been used as a minimally invasive treatment of patients with hypertrophic obstructive cardiomyopathy, resistant to conservative medical therapy. This catheter-based intervention consists of injecting absolute
Sotir Marchev, Boyko Kuzmanov
doaj +3 more sources